Dr. Mesinkovska is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1 medical plaza drive
Irvine, CA 92602Phone+1 216-444-5722
Education & Training
- Cleveland Clinic FoundationFellowship, Dermatopathology, 2012 - 2013
- Cleveland Clinic FoundationResidency, Dermatology, 2007 - 2012
- Mayo Clinic College of MedicineClass of 2007
Certifications & Licensure
- CA State Medical License 2014 - 2025
- HI State Medical License 2014 - 2016
- OH State Medical License 2007 - 2016
- American Board of Dermatology Dermatology
- American Board of Dermatology Dermatopathology
Clinical Trials
- Combined Focused Ultrasound and Calcium Hydroxylapatitie Filler for Skin Laxity and Volume Restoration Start of enrollment: 2019 Apr 19
Publications & Presentations
PubMed
- 69 citationsEfficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled studyBrett A. King, Justin M. Ko, Seth Forman, Manabu Ohyama, Natasha Atanaskova Mesinkovska
Journal of the American Academy of Dermatology. 2021-06-04 - 144 citationsTwo Phase 3 Trials of Baricitinib for Alopecia Areata.Brett King, Manabu Ohyama, Ohsang Kwon, Abraham Zlotogorski, Justin Ko
The New England Journal of Medicine. 2022-05-05 - 48 citationsThe Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meaningful success in clinical trials.Kathleen W. Wyrwich, Helen Kitchen, Sarah Knight, Natalie V. J. Aldhouse, Jake Macey
The British Journal of Dermatology. 2020-10-01
Press Mentions
- Evaluation of Pericardial Effusions in Alopecia Patients on Low-Dose Oral Minoxidil TherapySeptember 1st, 2024
- Leqselvi Can Achieve Nearly 90% Scalp Hair Coverage in Severe Alopecia Areata PatientsJuly 31st, 2024
- FDA Approves Deuruxolitinib for Alopecia AreataJuly 29th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: